Interactions : אינטראקציות

4.5   Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.
TRIOMEL 5 g/l nitrogen 990 kcal/l with electrolytes, emulsion for infusion must not be administered simultaneously with blood through the same infusion tubing because of the possibility of pseudoagglutination.

The lipids contained in this emulsion may interfere with the results of certain laboratory tests (for example, bilirubin, lactate dehydrogenase, oxygen saturation, blood haemoglobin) if the blood sample is taken before the lipids are eliminated (these are generally eliminated after a period of 5 to 6 hours without receiving lipids).

Precipitation of ceftriaxone-calcium can occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing intravenous solutions, including TRIOMEL 5 g/l nitrogen 990 kcal/l with electrolytes, emulsion for infusion, through the same infusion line (e.g., via Y-site).
However, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid (see sections 4.4 and 6.2).

If the same infusion line is used for sequential administration, the line must be thoroughly flushed with a compatible fluid (e.g. physiological salt-solution) to avoid precipitation.

TRIOMEL 5 g/l nitrogen 990 kcal/l with electrolytes, emulsion for infusion contains vitamin K, naturally present in lipid emulsions. The amount of vitamin K in recommended doses of TRIOMEL 5 g/l nitrogen 990 kcal/l with electrolytes, emulsion for infusion are not expected to influence effects of coumarin derivatives.

Due to the potassium content of TRIOMEL 5 g/l nitrogen 990 kcal/l with electrolytes, emulsion for infusion, special care should be taken in patients treated with potassium-sparing diuretics (e.g., amiloride, spironolactone, triamterene), angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus or cyclosporine in view of the risk of hyperkalemia.

Some medicinal products, like insulin, may interfere with the body’s lipase system. This kind of interaction seems, however, to be of limited clinical importance.

Heparin given in clinical doses causes a transient release of lipoprotein lipase into the circulation.
This may result initially in increased plasma lipolysis followed by a transient decrease in triglyceride clearance